GLP-1 receptor agonists — the class of medications that includes semaglutide, sold under brand names like Ozempic and Wegovy — have already reshaped how medicine approaches obesity and type 2 diabetes. Now, a rigorous clinical trial suggests these same drugs may help people with alcohol use disorder drink significantly less, opening a potential new front in addiction medicine.
The Clinical Trial: What Researchers Found
The study, published alongside a news release from the National Institutes of Health (NIH) on April 30, 2026, was a randomized, double-blind, placebo-controlled trial involving 108 adults diagnosed with both alcohol use disorder and obesity. Led by researchers Mette Kruse Klausen and Anders Fink-Jensen at Copenhagen University Hospital, participants were assigned to receive either weekly semaglutide injections or a placebo — both groups also underwent cognitive behavioral therapy (CBT) over 26 weeks.
The results were striking: the semaglutide group experienced a 41.1% reduction in heavy drinking days, which was 13.7 percentage points greater than the reduction seen in the placebo group. Blood-based biomarkers independently confirmed what participants self-reported, lending additional credibility to the findings.
Participants in the semaglutide group also showed more pronounced improvements in weight, blood pressure, and other clinical health markers — suggesting the drug may offer a dual benefit for people whose obesity and alcohol use disorder often reinforce each other.
Why the “NNT” Number Is So Significant
One of the most compelling statistics from the trial is the number needed to treat (NNT) — a measure of how many patients need to receive a treatment for one additional person to meaningfully benefit. For semaglutide in this context, the NNT was 4.3. By comparison, existing FDA-approved medications for alcohol use disorder — such as naltrexone and acamprosate — typically have NNTs of 7 or higher.
A lower NNT signals a more efficient treatment. While this trial was relatively small and further research is needed, the metric suggests semaglutide may be more effective per patient treated than current standard-of-care medications for this condition.
How GLP-1 Drugs May Affect Alcohol Cravings
Researchers are still working to fully understand the mechanism, but several theories have emerged. GLP-1 (glucagon-like peptide-1) receptors are found not only in the pancreas and gut, but also in the brain — particularly in reward and motivation circuits. These brain areas overlap substantially with the neural pathways involved in addictive behavior, including alcohol cravings.
Animal studies have previously suggested that GLP-1 agonists reduce the rewarding properties of alcohol, making it less desirable. The new human trial provides the strongest clinical evidence yet that this effect may translate to real-world drinking behavior.
Additionally, semaglutide slows gastric emptying and promotes feelings of satiety — effects that may subtly reduce impulsive consumption patterns, including the urge to drink.
A “Gamechanger” for the Treatment Gap?
Alcohol use disorder affects an estimated 400 million people worldwide, yet fewer than 10% receive any form of medical treatment. Stigma, limited access to specialist care, and the modest effectiveness of existing medications all contribute to this treatment gap.
“A new option that is more accessible and more effective could be a gamechanger for closing the treatment gap,” said George Koob, director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), in the NIH news release.
The fact that semaglutide is already widely prescribed and familiar to both clinicians and patients is particularly notable. If future trials confirm these findings at scale, integration into addiction treatment programs could be faster than it would be for a novel, never-approved compound.
Important Caveats to Keep in Mind
While the results are promising, experts urge caution before drawing broad conclusions. The trial enrolled only 108 participants — a relatively small sample for a condition affecting millions. Both groups also received cognitive behavioral therapy, which makes it difficult to fully isolate how much of the benefit came from semaglutide alone versus the drug-plus-therapy combination.
Longer-term follow-up data are also needed to determine whether the reduction in drinking is sustained after treatment ends. Side effects of semaglutide in the study were mild and primarily gastrointestinal, consistent with what has been reported in weight loss trials. Nevertheless, any consideration of semaglutide for alcohol use disorder requires careful evaluation by a qualified healthcare provider, given its known effects on blood sugar, weight, and metabolism.
What This Means for the Future of Addiction Medicine
This trial adds to a growing body of research suggesting that GLP-1 agonists may have behavioral and neurological effects that extend well beyond blood sugar control and weight management. Early-stage studies have also examined their potential in reducing cravings related to opioids, nicotine, and other substances — though alcohol now has the most robust human clinical trial data.
If follow-up trials replicate these findings in larger and more diverse populations, semaglutide could become the first major new pharmacological tool for alcohol use disorder in more than two decades. The research also raises broader questions about how metabolic and reward pathways are intertwined — and whether treating one can meaningfully influence the other.
What You Can Do Now
Research suggests that alcohol use disorder is a medical condition with evidence-based treatments, yet many people never seek help. If you or someone you know is struggling with alcohol dependence, speaking with a primary care physician or addiction specialist is the most important first step. Existing treatments, including naltrexone, acamprosate, and various behavioral therapies, already carry meaningful clinical evidence.
The emerging science on GLP-1 drugs adds a potentially exciting new option to the clinical toolkit — but as with all developing research, it is not yet a standard-of-care recommendation. Consult your healthcare provider about which treatment options may be appropriate for your specific situation.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.